🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Prolia 60 mg solution for injection in pre-filled syringe, LY06006

    Wuhan Createrna Science and Technology Co., Ltd

    Postmenopausal osteoporosis

    phase 3 small molecule active

    1 trial

  2. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  3. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  4. QTORIN 3.9% Rapamycin Anhydrous Gel

    PALVELLA THERAPEUTICS, INC.

    Microcystic Lymphatic Malformation

    phase 3 small molecule active

    1 trial

  5. QTORIN 3.9% rapamycin anhydrous gel

    PALVELLA THERAPEUTICS, INC.

    Pachyonychia Congenita

    phase 3 small molecule completed

    1 trial

  6. RECOMBINANT ADAMTS13 (rADAMTS13), RECOMBINANT ADAMTS13 (rADAMTS13)

    Baxalta Innovations GmbH

    Congenital Thrombotic thrombocytopenic purpura (cTTP)

    phase 3 small molecule active

    1 trial

  7. REGN10933 + REGN10987

    Regeneron UK Limited

    Healthy Participants

    phase 3 small molecule completed

    1 trial

  8. REGN1908

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule completed

    1 trial

  9. REGN1908-1909

    Regeneron UK Limited

    Allergic Rhinitis Due to Cat Allergy

    phase 3 small molecule terminated

    1 trial

  10. REGN2810

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  11. REGN2810/ipi

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  12. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  13. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  14. REGN475

    Regeneron UK Limited

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  15. REGN5713

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule active

    2 trials

  16. REGN5713

    Regeneron UK Limited

    Allergic Rhinitis

    phase 3 small molecule completed

    2 trials

  17. REGN7508

    Regeneron UK Limited

    Peripheral Artery Disease (PAD)

    phase 3 small molecule active

    1 trial

  18. REGN7508

    Regeneron UK Limited

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  19. REGN7508

    Regeneron UK Limited

    Cancer-Associated Thrombosis (CAT)

    phase 3 small molecule active

    1 trial

  20. REGN7508

    Regeneron UK Limited

    Atrial Fibrillation (AF)

    phase 3 small molecule active

    2 trials

  21. REGN7508

    Regeneron UK Limited

    Venous Thromboembolism (VTE)

    phase 3 small molecule active

    2 trials

  22. RESPIRATORY SYNCYTIAL VIRUS VACCINES

    The George Institute

    RSV infection

    phase 3 small molecule active

    1 trial

  23. RIMEGEPANT SULFATE, Placebo to rimegepant sulfate

    Pfizer Australia Pty Ltd

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  24. RITUXIMAB , SODIUM CHLORIDE, Placebo for lenalidomide 25mg, PREDNISONE , MINJUVI 200 mg powder for concentrate for solution for infusion, PREDNISOLONE , LENALIDOMIDE, DOXORUBICIN , Placebo for lenalidomide 10mg, VINCRISTINE , LENALIDOMIDE, Placebo for lenalidomide 15mg, LENALIDOMIDE, CYCLOPHOSPHAMIDE

    Incyte

    Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources